First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Clinical trial NCT03189719 · COMPLETED
Trial details
- NCT number
- NCT03189719
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-07-25
- Primary completion
- 2020-07-02
- Enrollment
- 749
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.